Literature DB >> 17469344

[Fibrinogen. Cardiovascular risk factor or marker?].

Luis M Canseco-Avila1, Carlos Jerjes-Sánchez, Rocío Ortiz-López, Augusto Rojas-Martínez, Denisse Guzmán-Ramírez.   

Abstract

UNLABELLED: Endothelial dysfunction and inflammation play a crucial role in all stages of atherosclerosis, from the beginning, during progression, and, finally, in its highest clinical expression: acute coronary syndromes. In this process, fibrinogen, an acute phase reactant with active participation in endothelial function, thrombosis and inflammation has proved to be an independent variable to cardiovascular risk together with its participation in resistance phenomena to different antithrombotic approaches. The reasons by which fibrinogen is elevated in cardiovascular disease and atherosclerosis are, in general, only incompletely understood; but all cells involved in the atherogenetic process are able to produce cytokines, which induce an acute phase reaction that increases fibrinogen levels in plasma. The potential pathophysiological mechanisms by which elevated fibrinogen levels mediate cardiovascular risk are multiple. Fibrinogen forms the substrate for thrombin an represents the final step in the coagulation cascade, it is essential for platelet aggregation, it modulates endothelial function, it promotes smooth muscle cell proliferation and migration, it interacts with the binding of plasmin with its receptor and, finally, it represents a major acute phase protein. Epidemiological studies have established sufficient evidence to consider fibrinogen as a strong, consistent, and independent cardiovascular risk marker or factor. Based on all these implications, the target of this review is an analysis of physiopathogenic and epidemiologic evidence searching for guidelines to establish whether fibrinogen as a risk factor or marker is the lost link between cardiovascular disease and classic risk factors.
CONCLUSION: Analyses of the respective studies suggest that fibrinogen is an important and independent cardiovascular risk factor, clearly associated with conventional risk factors and genetic polymorphisms. Whether or not fibrinogen is causally involved in atherothrombogenesis still remains to be determined and despite of unsolved issues that are waiting conclusive answers, fibrinogen has emerged as an important additional marker of cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17469344

Source DB:  PubMed          Journal:  Arch Cardiol Mex        ISSN: 1665-1731


  5 in total

1.  Nattokinase-heparin exhibits beneficial efficacy and safety-an optimal strategy for CKD patients on hemodialysis.

Authors:  Hao Wu; Huan Wang; Wei Li; Chi Zhang; Yushan Liu; Feng Xu; Jiepeng Chen; Lili Duan; Fengjiao Zhang
Journal:  Glycoconj J       Date:  2019-02-20       Impact factor: 2.916

2.  Evaluation of risk markers fluctuation during an initial therapy with rosiglitazon in patients suffering from metabolic syndrome.

Authors:  Amra Macić-Dzanković; Fuad Dzanković; Belma Pojskić; Zelija Velija-Asimi
Journal:  Bosn J Basic Med Sci       Date:  2009-11       Impact factor: 3.363

3.  Utilisation of Quartz Crystal Microbalance Sensors with Dissipation (QCM-D) for a Clauss Fibrinogen Assay in Comparison with Common Coagulation Reference Methods.

Authors:  Stephanie Oberfrank; Hartmut Drechsel; Stefan Sinn; Hinnak Northoff; Frank K Gehring
Journal:  Sensors (Basel)       Date:  2016-02-24       Impact factor: 3.576

4.  Effects of Atorvastatin on Oxidative Stress Biomarkers and Mitochondrial Morphofunctionality in Hyperfibrinogenemia-Induced Atherogenesis.

Authors:  María de la Paz Scribano; María Del Carmen Baez; Becerra Florencia; Mariana Denise Tarán; Signorini Franco; Ariel G Balceda; Mónica Moya
Journal:  Adv Med       Date:  2014-10-22

5.  iTRAQ-Based Quantitative Proteomics Analysis of the Protective Effect of Yinchenwuling Powder on Hyperlipidemic Rats.

Authors:  Zheyu Zhang; Wenbo Wang; Ling Jin; Xin Cao; Gonghui Jian; Ning Wu; Xia Xu; Ye Yao; Dongsheng Wang
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-14       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.